CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

CytomX Therapeutics, Inc.NASDAQ: CTMX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$17.94M, compared with $23.97M a year earlier. Trailing-twelve-month EBITDA was -$57.67M.

Context

  • EBITDA amounted to 20.7% of revenue in FY2025, down 3.8 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$52.64M (-234.1%) for the fiscal year ending Dec 2026, a slowdown from the -146.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.94M+30.9% QoQ
Last fiscal yearDec 2025
-$15.75M-146.5% YoY
LTMMar 2026
-$57.67M-232.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-174.8%-6678.6%-6503.8 pp
1 year-146.5%-234.1%-87.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(15.75M) USD
Year-over-year change
-146.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 EBITDA of -$57.67M is the 5th highest of the 10 companies compared; the peer median is -$75.93M.
  • Its year-over-year change of -232.5% is the lowest of 9, against a peer median of +7.1%.
  • EBITDA amounts to 162.2% of revenue for CTMX, versus a peer median of 106.5%.
CTMX Competitors Peer median
EBITDA for CTMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$322.61M +243.1%—46.0%
ZYMEZymeworks Inc.LTM Sep 2026$57.08M +205.8%—21.5%
ADAGAdagene Inc.LTM Jun 2024-$36.06M ——4420.7%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M -7.0%—32.2%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$57.67M -232.5%—162.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$75.93M +0.5%—547.9%
ADCTADC Therapeutics S.A.LTM Mar 2026-$83.2M +13.7%—105.1%
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M +42.0%—106.5%
XNCRXencor, Inc.LTM Jun 2026-$123.6M -14.3%—117.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$305.37M -38.1%—272652.7%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) -$75.93M+7.1%—106.5%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.